Vion Pharmaceuticals has extended its agreement with SAFC Pharma for the manufacture of the API in Cloretazine, an anti-cancer drug currently in a Phase III trial in combination with Ara-C for relapsed acute myelogenous leukemia (AML), and a Phase II trial for elderly de novo poor-risk AML. The agreement extends the original 2003 supply agreement to 2009. Production for the API will continue to be provided by SAFC Pharma’s high-potency manufacturing facility in Madison, WI. SAFC preside...